All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Mateon Therapeutics Inc. and Oncotelic Inc. completed the merger they announced on April 17. Oncotelic becomes a wholly owned subsidiary of Mateon, and the combined company has a pipeline of TGF-beta RNA therapeutics for late-stage cancers, including gliomas, pancreatic cancer and melanoma.